Science · 3 sources covering this

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

The trial ‌will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

3 L · 0 C · 0 R

How 3 sources are covering this

The HinduLean L·1h ago
Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
The trial ‌will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said
Read at The Hindu →
The HinduLean L·

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/33f181c995fe91020ea35b9923f08b94c9c6f44d"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Trial for Bundibugyo Ebola treatment starts in DRC, WHO says"></iframe>

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

How 3 sources are covering this

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

More from Science

Why diagnosing TB in children continues to be a challenge in India

MIB steps up pressure on Telegram; seeks proactive action against piracy

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

Google’s €4.1 billion Android fine: What the EU court ruled | Explained

Google loses fight against record €4.1 billion EU antitrust fine

Reader

Trust & legal

Across the network